Cell-cycle checkpoints and cancer

Nature

Volumn 432, Issue 7015, 2004, Pages 316-323

  Kastan, Michael B ^a   Bartek, Jiri ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RADIATION; SUN; TOXICITY;

CELL CYCLE; CELLULAR RESPONSES; SUN RADIATION;

TUMORS;

CHECKPOINT KINASE 2;

CANCER;

ANIMAL CELL; ATAXIA TELANGIECTASIA; ATM GENE; BREAST CANCER; CANCER; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL FATE; CELL PROLIFERATION; CELL VIABILITY; CHEK2 GENE; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; FAMILIAL CANCER; FANCONI ANEMIA; GENE; GENE TARGETING; GROWTH REGULATION; MAMMAL CELL; MRE11 GENE; NBS1 GENE; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; DNA DAMAGE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALIA; ATAXIA; ATAXIA TELANGIECTASIA; MAMMALIA;

EID: 9244251125     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03097     Document Type: Review

References (96)

1. Doll, R. & Peto, R. The causes of cancer in the United States today. J. Natl Cancer Inst. 66, 1192-1308 (1981).
2. Ford, J. M. Clinical Oncology (eds Abeloff, M. et al.) Ch. 11, 191-205 (Elsevier, Philadelphia, 2004).
3. Hartwell, L. H. & Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629-634 (1989).
4. Froelich-Ammon, S. J. & Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270, 21429-21432 (1995).
5. Shiloh, Y. & Kastan, M. B. ATM: genome stability, neuronal development, and cancer cross paths. Adv. Cancer Res. 83, 209-254 (2001).
6. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177-2196 (2001).
7. Kastan, M. B. & Lim, D.-S. The many substrates and functions of ATM. Mol. Cell Biol. 1, 179-186 (2000).
8. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
9. Kitagawa, R., Bakkenist, C. J., McKinnon, P. J. & Kastan, M. B. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 18, 1423-1438 (2004).
10. Uziel, T. et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 22, 5612-5621 (2003).
11. Carson, C. T. et al. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J. 22, 6610-6620 (2003).
12. Mochan, T. A., Venere, M., DiTullio, R. A. Jr & Halazonetis, T. D. 53BP1, an activator of ATM in response to DNA damage. DNA Repair (Amst) 3, 945-952 (2004).
13. Horejsi, Z. et al. Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene 23, 3122-3127 (2004).
14. Lee, J. H. & Paull, T. T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 304, 93-96 (2004).
15. Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling. Science 294, 1713-1716 (2001).
16. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548 (2003).
17. Unsal-Kacmaz, K. & Sancar, A. Quaternary structure of ATR and effects of ATRIP and replication protein A on its DNA binding and kinase activities. Mol. Cell Biol. 24, 1292-1300 (2004).
18. Osborn, A. J., Elledge, S. J. & Zou, L. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol. 12, 509-516 (2002).
19. Ellison, V. & Stillman, B. Opening of the clamp: an intimate view of an ATP-driven biological machine. Cell 106, 655-660 (2001).
20. Lin, S. Y., Li, K., Stewart, G. S. & Elledge, S. J. Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc. Natl Acad. Sci. USA 101, 6484-6489 (2004).
21. Zou, L., Cortez, D. & Elledge, S. I. Regulation of ATR substrate selection by Rad 17-dependent loading of Rad9 complexes onto chromatin. Genes Dev. 16, 198-208 (2002).
22. Brown, E. J. & Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17, 615-628 (2003).
23. Shechter, D., Costanzo, V. & Gautier, J. ATR and ATM regulate the timing of DNA replication origin firing. Nature Cell Biol. 6, 648-655 (2004).
24. Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T. & Giaccia, A. J. Hypoxia links ATR and p53 through replication arrest. Mol. Cell Biol. 22, 1834-1843 (2002).
25. Hekmat-Nejad, M., You, Z., Yee, M. C., Newport, I. W. & Cimprich, K. A. Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint. Curr. Biol. 10, 1565-1573 (2000).
26. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev. Cancer 3, 155-168 (2003).
27. Stucki, M. & Jackson, S. P. MDC1/NFBD1: a key regulator of the DNA damage response in higher eukaryotes. DNA Repair (Amst) 3, 953-957 (2004).
28. Chini, C. C. & Chen, J. Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst) 3, 1033-1037 (2004).
29. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
30. Lukas, C., Falck, J., Bartkova, J., Bartek, J. & Lukas, J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nature Cell Biol. 5, 255-260 (2003).
31. Lukas, C. et al. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J. 23, 2674-2683 (2004).
32. Celeste, A. et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nature Cell Biol. 5, 675-679 (2003).
33. Goldberg, M. et al. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421, 952-956 (2003).
34. Huyen, Y. et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature doi: 10.1038/nature03114 (in the press).
35. Lou, Z., Minter-Dykhouse, K., Wu, X. & Chen, J. MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature 421, 957-961 (2003).
36. Shang, Y. L., Bodero, A. J. & Chen, P. L. NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response. J. Biol. Chem. 278, 6323-6329 (2003).
37. Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. & Elledge, S. J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421, 961-966 (2003).
38. Xu, X. & Stern, D. F. NFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathways. J. Biol. Chem. 278, 8795-8803 (2003).
39. DiTullio, R. A. Jr et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biol. 4, 998-1002 (2002).
40. Ward, I. M., Minn, K., van Deursen, J. & Chen, J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell Biol. 23, 2556-2563 (2003).
41. Wang, B., Matsuoka, S., Carpenter, P. B. & Elledge, S. J. 53BP1, a mediator of the DNA damage checkpoint. Science 298, 1435-1438 (2002).
42. Manke, I. A., Lowery, D. M., Nguyen, A. & Yaffe, M. B. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302, 636-639 (2003).
43. Yu, X., Chini, C. C., He, M., Mer, G. & Chen, J. The BRCT domain is a phospho-protein binding domain. Science 302, 639-642 (2003).
44. Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905-916 (1999).
45. D'Amours, D. & Jackson, S. P. The mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nature Rev. Mol. Cell Biol. 3, 317-327 (2002).
46. Petrini, J. H. & Stracker, T. H. The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol. 13, 458-462 (2003).
47. Lee, J., Kumagai, A. & Dunphy, W. G. Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17. Mol. Cell 11, 329-340 (2003).
48. Sorensen, C. S., Syljuasen, R. G., Lukas, J. & Bartek, J. ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chik1 and Cdc25A in the absence of DNA damage. Cell Cycle 3, 941-945 (2004).
49. Krämer, A. et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nature Cell Biol. 9, 884-891 (2004).
50. Bartek, J., Bartkova, J. & Lukas, J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237, 1-6 (1997).
51. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002).
52. Wahl, G. M. & Carr, A. M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nature Cell Biol. 3, E277-E286 (2001).
53. Craig, A. et al. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep. 4, 787-792 (2003).
54. Maya, R. et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15, 1067-1077 (2001).
55. Bartek, J., Lukas, C. & Lukas, J. Checking on DNA damage in S phase. Nature Rev. Mol. Cell Biol. 5, 792-804 (2004).
56. Donzelli, M. & Draetta, G. F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677 (2003).
57. Kim, S. T., Xu, B. & Kastan, M. B. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev. 16, 560-570 (2002).
58. Yazdi, P. T. et al. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev. 16, 571-582 (2002).
59. Taniguchi, T. et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-472 (2002).
60. Nakanishi, K. et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nature Cell Biol. 4, 913-920 (2002).
61. Falck, J., Petrini, J. H., Williams, B. R., Lukas, J. & Bartek, J. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nature Genet. 30, 290-294 (2002).
62. Pichierri, P. & Rosselli, F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 23, 1178-1187 (2004).
63. Costanzo, V. et al. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol. Cell 11, 203-213 (2003).
64. Xu, B., Kim, S.-T., Lim, D.-S. & Kastan, M. B. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 22, 1049-1059 (2002).
65. Nyberg, K. A., Michelson, R. J., Putnam, C. W. & Weinert, T. A. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 36, 617-656 (2002).
66. Katsuhiro, U., Daigo, I., Ken, S., Nobushige, N. & Noriyuki, S. CHK1, but not CHK2, inhibits Cdc25 phosphatases by a novel common, mechanism. EMBO J. (in the press).
67. Mailand, N. et al. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 21, 5911-5920 (2002).
68. Bulavin, D. V. et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411, 102-107 (2001).
69. Xu, B., Kim, S. & Kastan, M. B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell Biol. 21, 3445-3450 (2001).
70. Taylor, W. R. & Stark, G. R. Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815 (2001).
71. Zhou, B. B. & Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev. Cancer 4, 216-225 (2004).
72. Treuner, K., Helton, R. & Barlow, C. Loss of Rad52 partially rescues tumorigenesis and T-cell maturation in Atm-deficient mice. Oncogens 23, 4655-4661 (2004).
73. Stewart, G. S. et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99, 577-587 (1999).
74. Carney, J. P. et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93, 477-486 (1998).
75. Varon, R. et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93, 467-476 (1998).
76. O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia- telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nature Genet. 33, 497-501 (2003).
77. Bobabilla-Morales, L. et al. Chromosome instability induced in vitro with mitomycin C in five Seckel syndrome patients. Am. J. Med. Genet. 123, 148-152 (2003).
78. Fang, Y. et al. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J. 23, 3164-3174 (2004).
79. Bassing, C. H. et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114, 359-370 (2003).
80. Celeste, A. et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114, 371-383 (2003).
81. Canman, C. E. Checkpoint mediators: relaying signals from DNA strand breaks. Curr. Biol. 13, R48S-R490 (2003).
82. Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448-1459 (2000).
83. Lam, M. H., Liu, Q., Elledge, S. J. & Rosen, J. M. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6, 45-59 (2004).
84. Hirao, A. et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell Biol. 22, 6521-6532 (2002).
85. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528-2531 (1999).
86. King, M. C., Marks, J. H. & Mandell, J. B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).
87. Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (2002).
88. Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genet. 22, 37-43 (1999).
89. Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genet. 28, 266-271 (2001).
90. McPherson, J. P. et al. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev. 18, 1144-1153 (2004).
91. Kraakman-van der Zwet, M. et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell Biol. 22, 669-679 (2002).
92. Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
93. D'Andrea, A. D. The Fanconi road to cancer. Genes Dev. 17, 1933-1936 (2003).
94. Lee, H. et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell 4, 1-10 (1999).
95. Theunissen, J. W. et al. Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11 (ATLD1/ATLD1) mice. Mol. Cell 12, 1511-1523 (2003).
96. Liu, G. et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genet. 36, 63-68 (2004).